Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2021 Oct 22

PMID 34677243

Citations 4

Authors

Arshia Beigi

Saba Vafaei-Nodeh

Longlong Huang

Shaun Z Sun

Jenny J Ko

Affiliations

Soon will be listed here.

Abstract

Background: Real-world data on palliative systemic therapies (PST) in treating metastatic bladder cancer (mBC) is limited. This study investigates current trends in treating mBC with first- (1L) and second-line (2L) chemotherapy (CT) and immunotherapy (IT).

Methods: A chart review was conducted on patients diagnosed with stage II-IV bladder cancer in 2014-2016. Survival outcomes were compared between chemotherapy, immunotherapy, and supportive care.

Results: out of 297 patients, 77% were male. 44% had stage IV disease at diagnosis. Median age at metastasis was 73 years. 40% of patients received 1L PST and 34% received 2L PST. Median overall survival (mOS) was longer in those receiving PST versus no treatment ( < 0.001). Patients receiving CT and IT sequentially had the longest mOS (18.99 months). First-line IT and CT mOS from treatment start dates were 5.03 and 9.13 months, respectively ( = 0.81). Gemcitabine with cisplatin (8.88 months) or carboplatin (9.13 months) were the most utilized 1L chemotherapy regimens ( = 0.85). 2L IT and CT mOS from treatment start dates were 6.72 and 3.78 months, respectively ( = 0.15).

Conclusion: real-world mOS of >1.5 years in mBC is unprecedented and supports using multiple lines of PST. Furthermore, immunotherapy may be a comparable alternative to chemotherapy in both 1L and 2L settings.

Citing Articles

Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors.

Cheng L, Su P, Kuo M, Lin C, Luo H, Chou C Ther Adv Med Oncol. 2024; 16:17588359241305091.

PMID: 39687055 PMC: 11648016. DOI: 10.1177/17588359241305091.

Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions.

Srinivasalu V, Robbrecht D Cancers (Basel). 2024; 16(13).

PMID: 39001460 PMC: 11240521. DOI: 10.3390/cancers16132398.

Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.

Asakawa K, Waratani M, Massey O, Holbrook T, Kondo M, Saito A Int J Urol. 2024; 31(7):730-738.

PMID: 38468564 PMC: 11524106. DOI: 10.1111/iju.15450.

Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.

Ogura R, Ito S, Ueda T, Gabata Y, Sako S, Inoue Y Sci Rep. 2023; 13(1):19517.

PMID: 37945655 PMC: 10636091. DOI: 10.1038/s41598-023-46977-1.

Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis.

Kearney M, Zhang L, Hubscher E, Musat M, Harricharan S, Wilke T Future Oncol. 2023; 20(16):1123-1137.

PMID: 37526215 PMC: 11727863. DOI: 10.2217/fon-2023-0298.

References

Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat A . Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol. 2019; 15(12):1323-1334. DOI: 10.2217/fon-2018-0654. View

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View

Chalasani V, Chin J, Izawa J . Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009; 3(6 Suppl 4):S193-8. PMC: 2792446. DOI: 10.5489/cuaj.1195. View

Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A . Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007; 52(1):134-41. DOI: 10.1016/j.eururo.2006.12.029. View

Feld E, Harton J, Meropol N, Adamson B, Cohen A, Parikh R . Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. Eur Urol. 2019; 76(4):524-532. PMC: 6822167. DOI: 10.1016/j.eururo.2019.07.032. View

Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G . Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27(27):4454-61. DOI: 10.1200/JCO.2008.20.5534. View

De Santis M, Bellmunt J, Mead G, Kerst J, Leahy M, Maroto P . Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2011; 30(2):191-9. PMC: 3255563. DOI: 10.1200/JCO.2011.37.3571. View

Fradet Y, Bellmunt J, Vaughn D, Lee J, Fong L, Vogelzang N . Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019; 30(6):970-976. PMC: 6594457. DOI: 10.1093/annonc/mdz127. View

10.

von der Maase H, Sengelov L, Roberts J, Ricci S, Dogliotti L, Oliver T . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23(21):4602-8. DOI: 10.1200/JCO.2005.07.757. View

11.

Balar A, Galsky M, Rosenberg J, Powles T, Petrylak D, Bellmunt J . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 389(10064):67-76. PMC: 5568632. DOI: 10.1016/S0140-6736(16)32455-2. View

12.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

13.

Furubayashi N, Negishi T, Yamashita T, Kusano S, Taguchi K, Shimokawa M . The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Mol Clin Oncol. 2017; 7(6):1112-1118. PMC: 5740837. DOI: 10.3892/mco.2017.1452. View

14.

Bellmunt J, von der Maase H, Mead G, Skoneczna I, De Santis M, Daugaard G . Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012; 30(10):1107-13. PMC: 3341152. DOI: 10.1200/JCO.2011.38.6979. View

15.

Tsang E, Forbes C, Chi K, Eigl B, Parimi S . Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis. Curr Oncol. 2019; 26(2):e260-e265. PMC: 6476464. DOI: 10.3747/co.26.4070. View

16.

Malkowicz S, van Poppel H, Mickisch G, Pansadoro V, Thuroff J, Soloway M . Muscle-invasive urothelial carcinoma of the bladder. Urology. 2007; 69(1 Suppl):3-16. DOI: 10.1016/j.urology.2006.10.040. View

17.

Witjes J, Comperat E, Cowan N, De Santis M, Gakis G, Lebret T . EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2013; 65(4):778-92. DOI: 10.1016/j.eururo.2013.11.046. View

18.

Fisher M, Shenolikar R, Miller P, Fenton M, Walker M . Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015. Clin Genitourin Cancer. 2018; 16(6):e1171-e1179. DOI: 10.1016/j.clgc.2018.07.025. View

19.

Choueiri T, Ross R, Jacobus S, Vaishampayan U, Yu E, Quinn D . Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2011; 30(5):507-12. PMC: 4104290. DOI: 10.1200/JCO.2011.37.7002. View

20.

Amin M, Greene F, Edge S, Compton C, Gershenwald J, Brookland R . The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67(2):93-99. DOI: 10.3322/caac.21388. View